Building Better Cancer Vaccines: The Progress and Promise of R&D

Table of Contents

• Executive Summary
  • Strategic Considerations
  • Stakeholder Implications
• Cancer Vaccines: A New Weapon
• Tumor Immunology
• The Cancer Vaccine Concept
  • Preventive Cancer Vaccines
    • Merck' s Gardasil
    • GlaxoSmithKline' s Cervarix
  • Therapeutic Cancer Vaccines
• Cancer Vaccine Strategies
  • Cell-Based Vaccines
    • Autologous Whole Tumor Cell Vaccines
    • Allogeneic Whole Tumor Cell Vaccines
    • Genetically Modifi ed Whole Tumor Cell Vaccines
    • Dendritic Cell Vaccines
  • Protein-Based Vaccines
    • Peptide-Based Vaccines
    • Heat-Shock-Protein-Based Vaccines
  • Vector-Based Vaccines
    • Virus-Based Vaccines
    • Bacteria-Based Vaccines
    • DNA-Based Vaccines
• Use of Adjuvants to Improve Cancer Vaccine Effi cacy
• Future Considerations
  • Addressing Key Development Questions
  • The Need for Collaborations

Tables:

• 1. Infectious Agents Associated with Cancer Development
• 2. Advantages and Disadvantages of Therapeutic Cancer Vaccine Strategies
• 3. Select Cancer Vaccines in Development, 2007
• 4. Select Cancer Vaccine Adjuvants in Development, 2007
• 5. The Cancer Vaccine Consortium

Figures:

• 1. Number of Cancer Vaccines by Phase of Clinical Development, 2007